Biomarkers for the diagnosis and management of Parkinson's disease

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 1, 2013, Pages 71-83

  Waragai, Masaaki ^a   Sekiyama, Kazunari ^a   Fujita, Masayo ^a   Tokuda, Takahiko ^b   Hashimoto, Makoto ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Biomarkers; Diagnosis; Management; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 6 FLUORODOPA F 18; ADIPONECTIN; ALPHA SYNUCLEIN; ALTROPANE; BIOLOGICAL MARKER; CARBON 11; DIHYDROTETRABENAZINE; DJ 1 PROTEIN; IOMETOPANE I 123; LEPTIN; METHYLPHENIDATE; N (3 IODOPROPEN 2 YL) 2BETA CARBOMETHOXY 3BETA (4 CHLOROPHENYL)TROPANE; N OMEGA FLUOROPROPYL 2BETA CARBOXYMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; RACLOPRIDE C 11; RTI 32 C 11; TRACER; UNCLASSIFIED DRUG; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M;

AUTONOMIC DYSFUNCTION; BODY FLUID; BRAIN SCINTISCANNING; CEREBROSPINAL FLUID; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EARLY DIAGNOSIS; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL TREMOR; EYE MOVEMENT DISORDER; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HUMAN; INHERITANCE; ISOTOPE LABELING; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OLFACTORY SYSTEM; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; METABOLISM;

BIOLOGICAL MARKERS; HUMANS; PARKINSON DISEASE;

EID: 84871570203     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.733694     Document Type: Review

References (85)

1. Mizuno Y, Hattori N, Kubo S, et al. Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci 2008;363:2215-27
2. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76
3. Tolosa E, Gaig C, Santamaria J, Compta Y. Diagnosis and the premotor phase of Parkinson disease. Neurology 2009;72(7 Suppl):S12-20
4. Hughes AJ, Daniel SE, Ben-Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-70
5. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006;63:584-8
6. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-82
7. Marek K, Jennings D, Tamagnan G, Seibyl J. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann Neurol 2008;64(Suppl 2):S111-21.
8. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology 2009;72(7 Suppl):S21-6; Review
9. Goldstein DS, Holmes C, Bentho O, et al. Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008;14:600-7
10. Haehner A, Hummel T, Hummel C, et al. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 2007;22:839-42
11. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008;63(2):167-73
12. Siderowf A, Jennings D, Eberly S, et al. Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord 2012;27:406-12
13. Wenning GK, Shephard B, Hawkes C, et al. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 1995;91:247-50
14. Doty RL, Singh A, Tetrud J, Langston JW. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol 1992;32:97-100
15. Millar Vernetti P, Perez Lloret S, Rossi M, et al. Validation of a new scale to assess olfactory dysfunction in patients with Parkinson's disease. Parkinsonism Relat Disord 2012;18:358-61
16. Hummel T, Sekinger B, Wolf SR, et al. 'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 1997;22:39-52
17. Khan NL, Katzenschlager R, Watt H, et al. Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 2004;62:1224-6
18. Baba T, Kikuchi A, Hirayama K, et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. Brain 2012;135:161-9
19. Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296-300
20. Evatt ML, Chaudhuri KR, Chou KL, et al. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation-critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord 2009;24:635-46
21. Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 3):S224-32
22. Goldstein DS, Sewell L, Sharabi Y. Autonomic dysfunction in PD: a window to early detection? J Neurol Sci 2011;310:118-22
23. Bloch A, Probst A, Bissig H, et al. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006;32:284-95
24. Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999;52:1269-71
25. Devos D, Kroumova M, Bordet R, et al. Heart rate variability and Parkinson's disease severity. J Neural Transm 2003;110:997-1011
26. Kallio M, Haapaniemi T, Turkka J, et al. Heart rate variability in patients with untreated Parkinson's disease. Eur J Neurol 2000;7:667-72
27. Valappil RA, Black JE, Broderick MJ, et al. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord 2010;25:2296-303
28. Postuma RB, Lanfranchi PA, Blais H, et al. Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov Disord 2010;25:2304-10
29. Crawford T, Goodrich S, Henderson L, Kennard C. Predictive responses in Parkinson's disease: manual keypresses and saccadic eye movements to regular stimulus events. J Neurol Neurosurg Psychiatry 1989;52:1033-42
30. Lueck CJ, Tanyeri S, Crawford TJ, et al. Antisaccades and remembered saccades in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:284-8
31. Vermersch AI, Rivaud S, Vidailhet M, et al. Sequences of memory-guided saccades in Parkinson's disease. Ann Neurol 1994;35:487-90
32. MacAskill MR, Anderson TJ, Jones RD. Adaptive modification of saccade amplitude in Parkinson's disease. Brain 2002;125:1570-82
33. Kimmig H, Haussmann K, Mergner T, Lucking CH. What is pathological with gaze shift fragmentation in Parkinson's disease? J Neurol 2002;249:683-92
34. Blekher T, Weaver M, Rupp J, et al. Multiple step pattern as a biomarker in Parkinson disease. Parkinsonism Relat Disord 2009;15(7):506-10
35. Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson's disease. Lancet Neurol 2011;10:987-1001
36. Cummings JL, Henchcliffe C, Schaier S, et al. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 2011;134:3146-66
37. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-212
38. Dentresangle C, Veyre L, Le Bars D, et al. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F] dopa and [11C]raclopride PET study. Mov Disord 1999;14:1025-30
39. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology 1993;43(12 Suppl 6):S6-16
40. Sawle GV. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography? Mov Disord 1993;8:271-7
41. Eidelberg D. Brain networks and clinical penetrance: lessons from hyperkinetic movement disorders. Curr Opin Neurol 2003;16:471-4
42. Eidelberg D. The assessment of neurological systems with functional imaging. Brain Lang 2007;102:192-9
43. Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci 2009;32:548-57
44. Poston KL, Eidelberg D. Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiol Dis 2009;35:141-7
45. Poston KL, Eidelberg D. FDG PET in the evaluation of Parkinson's disease. PET Clin 2010;5:55-64
46. Poston KL, Eidelberg D. Functional brain networks and abnormal connectivity in the movement disorders. Neuroimage 2012;62:2261-70
47. Fukuda M, Edwards C, Eidelberg D. Functional brain networks in Parkinson's disease. Parkinsonism Relat Disord 2001;8:91-4
48. Lozza C, Baron JC, Eidelberg D, et al. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 2004;22:236-45
49. Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. Parkinsonism Relat Disord 2007;13(Suppl 3):S425-8
50. Waragai M, Yamada T, Matsuda H. Evaluation of brain perfusion SPECT using an easy Z-score imaging system (eZIS) as an adjunct to early-diagnosis of neurodegenerative diseases. J Neurol Sci 2007;260:57-64
51. Orimo S, Ozawa E, Nakade S, et al. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:189-94
52. Spiegel J. Diagnostic and pathophysiological impact of myocardial MIBG scintigraphy in Parkinson's disease. Parkinsons Dis 2010;2010:p. 295346
53. Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005;20:1278-85
54. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008;7:1044-55
55. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70:1411-17
56. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-84.
57. Kwon DH, Kim JM, Oh SH, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267-77
58. Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006;129:2679-87
59. Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple systematrophy from PD. Neurology 2002;58:575-80
60. Paviour DC, Thornton JS, Lees AJ, Jager HR. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Mov Disord 2007;22(1):68-74
61. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-93
62. Davie CA. A review of Parkinson's disease. Br Med Bull 2008;86:109-27
63. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18(R1):R48-59
64. International Parkinson Disease Genomics Consortium. Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011;377(9766):641-9
65. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003;302(5646):841
66. Funayama M, Hasegawa K, Kowa H, et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11. 2-q13.1. Ann Neurol 2002;51:296-301
67. Brice A. Genetics of Parkinson's disease: LRRK2 on the rise. Brain 2005;128:2760-2
68. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-80
69. Anheim M, Elbaz A, Lesage S, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012;78(6):417-20
70. Wilkins EJ, Rubio JP, Kotschet KE, et al. A DNA resequencing array for genes involved in Parkinson's disease. Parkinsonism Relat Disord 2012;18:386-90
71. Waragai M, Sekiyama K, Sekigawa A, et al. alpha-synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's disease. Int J Mol Sci 2010;11(11):4257-66
72. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10(3):230-40
73. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133(Pt 3):713-26
74. Yanamandra K, Gruden MA, Casaite V, et al. alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One 2011;6(4):e18513
75. Lehnert S, Jesse S, Rist W, et al. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol 2012;234(2):499-505
76. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88
77. Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci USA 2007;104:5860-5
78. Ishigami N, Tokuda T, Ikegawa M, et al. Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy. Mov Disord 2012;27:851-7
79. Cassani E, Cancello R, Cavanna F, et al. Serum adiponectin levels in advanced-stage Parkinson's disease patients. Parkinsons Dis 2011;2011:624764
80. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8
81. Lohmann E, Periquet M, Bonifati V, et al. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003;54:176-85
82. Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004;56:336-441
83. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-9
84. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006;38:1184-91
85. Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005;14:2099-11